We engineer
and manufacture

platelets.

Inspired by platelet biology to save lives

HemostOD’s technology platform unlocks the power of platelets in:

Thrombocytopenia

(lead program 1)

Developing universal* platelets for treatment in patients with, or at risk of, HLA immune-refractoriness.

Tissue-targeted cargo delivery

(lead program 2)

Using our unique CAR-PLT® technology for shielded delivery of miRNA/siRNA or proteins to specific target tissues.

Regenerative medicine

Using engineered platelets in wound healing, anti-inflammatory and immunomodulating applications.

Culture of therapeutic stem cells

Using platelet lysate produced from our universal platelets to boost cell proliferation.

* engineered to be HLA-null

HemostOD: a swiss-based preclinical company

Founded in 2020, HemostOD is a biotech company based at the EPFL Innovation Park in Lausanne, Switzerland.

We are a preclinical stage company developing applications based on our proprietary platform to engineer and manufacture universal platelets.

A unique & scalable

platelet manufacturing

platform

Inspired by the physiological generation of platelets in the bone marrow, HemostOD has developed an innovative solution to manufacture engineered platelets, thereby providing a practically unlimited source of universal platelets.

Our unique process integrates: molecular & cell biology techniques to build a stable megakaryocitic cell line (steps 1, 2 & 3), followed by the use of advanced microfluidic technologies in a bioreactor to fragment megakaryocytes into platelets (step 4). This robust and rapid process enables the generation of large quantities of homogeneous and high-quality platelets in a few hours.

Our IP-protected platform includes:

Immortalization of hematopoietic progenitors (stem) cells from a single donor.

Engineering of cells to introduce custom features, modifying the platelet surface and/or content for controlled release.

Differentiation into a practically unlimited source of megakaryocytes, the platelet progenitor cells.

Ex-vivo generation of platelets in a robust, fast and scalable manufacturing process.

HemostOD cell line

Engineered

HemostOD cell line

Megakaryocytes

Platelets

Partnering opportunities

We are open to collaboration and welcome enquiries about partnership opportunities for applications in all our target areas:

Thrombocytopenia,
Tissue-targeted cargo delivery technology (CAR-PLT®),
Regenerative medicine,
Culture of therapeutic stem cells (platelet lysate),

and beyond.

For enquiries, please contact: contact@hemostod.com

A multidisciplinary team

Faouzi Khechana

CEO

Laurent Massuyeau

Executive Chairman

Laurent Burnier

CSO

Elodie Dahan

CTO

Prof. Olaïa Naveiras

Faouzi Khechana

CEO

Laurent Massuyeau

Executive Chairman

Anton Gueth

Board member

Yves Glanzmann

Board member

HemostOD enters EIT Health’s Gold Track Programme

04/11/2023

HemostOD has been recognized as a promising healthcare company by a jury of experts. The team will now receive tailored support to grow the company.

Partnering with the Swiss Biotech Center

02/04/2023

HemostOD partners with the Swiss Biotech Center to pre-industrialize its technology. Thanks to this new partnership HemostOD will benefit from solid expertise and state-of-the-art infrastructure

Tech Seed loan

03/05/2022

HemostOD receives CHF 100’000 from the Foundation for Technological Innovation (FIT).

Seed Round

02/09/2021

HemostOD raises CHF 1.7M in seed round financing.

Join us

We do not have any open positions at the moment, but we are always happy to hear from interested talents. Please reach out to us by email at the address below